| March 22, 2013 |
| Dr. Antoni Ribas Discusses PD1 and PD-L1 Targeted Cancer Drugs |
 |
Antoni Ribas, M.D. is involved in trials testing new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. In the video interview, Dr. Ribas explains the trial test data published so far, and previews new data to come. |
| January 22, 2013 |
| Dr. Richard Finn on Pioneering New Treatment for Aggressive Breast Cancer |
 |
Scientists at UCLA’s Jonsson Comprehensive Cancer Center have recently reported an encouraging increase in progression-free survival for patients with HER2-negative breast cancer. In this informative video, lead researcher Dr. Richard Finn explains the positive results of this pioneering study and the possibilities it opens up for future breast cancer treatments. |
| October 5, 2012 |
| Dr. Antoni Ribas Discusses New Combination Therapy to Treat Metastatic Melanoma |
 |
In this 13-minute interview, Dr. Antoni Ribas of UCLA's Jonsson Comprehensive Cancer Center provides an extesnive overview of the latest positive advancements in the use of combined BRAF and MEK inhibitors to treat metastic melanoma. These latest findings provide strong support for testing the combination therapy in future human clinical trials, which Jonsson Cancer Center researchers hope to launch within two years. |
| May 30, 2012 |
| We Need to Talk |
 |
During formation of multi-cellular organisms, cells need to talk to each other to make critical decisions as to what kind of cell to become. The Notch signaling system allows cells to directly talk to each other to program almost every cell type in the body. Now, researchers from UCLA’s Jonsson Comprehensive Cancer Center have shown for the first time that the mechanical force produced by cell-cell interactions is critical for programming by the Notch signaling system. |
| May 15, 2012 |
| JCCC Director Judy Gasson, Ph.D.: Advancements in Cancer Research at UCLA |
 |
Dr. Judith Gasson, Director of UCLA's Jonsson Comprehensive Cancer Center (JCCC), discusses research areas within the JCCC that are making tremendous headway in cancer treatment and detection. Advancements in stem cell research, nanotechnology, imaging, and translational research at the JCCC are making measurable progress and saving lives every day. |
| April 10, 2012 |
| Dr. Dennis Slamon Discusses the Importance of Participating in Clinical Trials |
 |
HER2+ metastatic breast cancer is a particularly aggressive form of the disease, and currently accounts for about one in every five breast cancer diagnoses. In this moving profile, HER2+ metastatic breast cancer survivor Dr. Kathy Bennett, who was diagnosed with the disease in 2008, and UCLA Jonsson Comprehensive Cancer Center researcher and Herceptin pioneer Dr. Dennis Slamon, discuss how clinical trials turn survivors and scientists into colleagues, uniting them in the fight to stop this deadly disease. |
| May 4, 2010 |
| UCLA Fights Cancer and Gives Hope to Patients |
 |
Meet cancer patients and family members touched by new therapies developed at UCLA's Jonsson Cancer Center. Features appearances by Ryan Seacrest, Khloe Kardashian and the Kardashian family, Denise and Peter Wittich, Laura Felkai, and Meritt Carlberg, the widow of cancer patient Kevin Carlberg. |
| May 3, 2010 |
| PSTD in Cancer Survivors |
 |
Dr. Margaret Stuber, a researcher with UCLA's Jonsson Comprehensive Cancer Center, found that young adult cancer survivors are four times more likely to develop Post-traumatic Stress Disorder. The results of the study appear Monday in the journal Pediatrics. |
| April 29, 2010 |
| UCLA's Dr. Dennis Slamon Talks Stem Cell Research (Pt. 1) (Pt. 2) (Pt. 3) (Pt. 4) |
 |
Dr. Dennis Slamon, director of clinical/translational research at UCLA's Jonsson Comprehensive Cancer Center, talks about his cancer research at a public forum April 15 sponsored by the California Instittue of Regnerative Medicine (CIRM). |
| June 2009 |
| Vons Donates $700,000 to Support Cancer Research |
 |
In conjunction with Breast Cancer Awareness Month in October, VONS, a Safeway Company, launched a month-long fundraising campaign that allowed customers to make a donation when checking out to support cancer research. |
| April 2009 |
| UCLA Unveils New Non-Invasive Stereotactic Radiosurgery Machine |
 |
Dr. Percy Lee, assistant professor of radiation oncology at UCLA, director of the stereotactic body radiation therapy program and a Jonsson Cancer Center researcher, discusses the use of a new tool recently acquired by UCLA to treat radiation patients in fewer visits and help them suffer from fewer side effects. |
| March 2009 |
| UCLA acquires tool that delivers higher doses of radiation in less time |
 |
UCLA's Jonsson Comprehensive Cancer Center is now treating a variety of cancers with the new Novalis TX, a state-of-the-art image-guided device that provides more accurate, concentrated doses of radiation, allowing patients to be treated in fewer visits and suffer from fewer side effects. |
| November 2008 |
| Breast cancer drug Herceptin is a lifesaver |
 |
Herception--a targeted therapy breast cancer drug developed at UCLA's Jonsson Comprehensive Cancer Center--saved the life of Louise Cooper, who is still going strong 10 years after receiving a cancer diagnosis. |
Last updated: 4/4/2013 2:48:31 PM